Abstract
Prior to the discovery of insulin, the major cause of death in the diabetic population was ketoacidosis. Although insulin and improved glycemic control have improved the longevity of diabetic patients, they still suffer from significant morbidity and mortality due to chronic secondary complications. Long standing diabetes leads to structural and functional alterations in both the micro- and macrovasculature. These complications, involving the retina, kidney, and peripheral nerves, as well as cardiovascular system, severely compromise the quality and expectancy of life. Large scale clinical trials have identified hyperglycemia as the key determinant for the development of such complications. Therapeutic modalities have been developed to target glucose-induced alterations, such as protein kinase C activation, augmented polyol pathway activity, non-enzymatic glycation and oxidative stress to ameliorate chronic complications. However, clinical trials targeting these biochemical alterations have failed to show significant beneficial effects. The plethora of biochemical anomalies that govern the development of chronic diabetic complications may therefore be subject to cross-interaction and complex interplays. Studies in both animal and human diabetes have, however, showed alteration of several vasoactive effector molecules such as endothelins. These molecules may be instrumental in mediating diabetes-induced structural and functional deficits at both the early and late stages of the disease. This review will discuss the current mechanistic understanding of chronic diabetic complications and will explore the potential novel therapeutic interventions.
Keywords: Diabetes, aldose reductase, protein kinase C, advanced glycation end products, oxidative stress, endothelin, fibronectin
Current Vascular Pharmacology
Title: Towards Newer Molecular Targets for Chronic Diabetic Complications
Volume: 4 Issue: 1
Author(s): Zia A. Khan, Hana Farhangkhoee and Subrata Chakrabarti
Affiliation:
Keywords: Diabetes, aldose reductase, protein kinase C, advanced glycation end products, oxidative stress, endothelin, fibronectin
Abstract: Prior to the discovery of insulin, the major cause of death in the diabetic population was ketoacidosis. Although insulin and improved glycemic control have improved the longevity of diabetic patients, they still suffer from significant morbidity and mortality due to chronic secondary complications. Long standing diabetes leads to structural and functional alterations in both the micro- and macrovasculature. These complications, involving the retina, kidney, and peripheral nerves, as well as cardiovascular system, severely compromise the quality and expectancy of life. Large scale clinical trials have identified hyperglycemia as the key determinant for the development of such complications. Therapeutic modalities have been developed to target glucose-induced alterations, such as protein kinase C activation, augmented polyol pathway activity, non-enzymatic glycation and oxidative stress to ameliorate chronic complications. However, clinical trials targeting these biochemical alterations have failed to show significant beneficial effects. The plethora of biochemical anomalies that govern the development of chronic diabetic complications may therefore be subject to cross-interaction and complex interplays. Studies in both animal and human diabetes have, however, showed alteration of several vasoactive effector molecules such as endothelins. These molecules may be instrumental in mediating diabetes-induced structural and functional deficits at both the early and late stages of the disease. This review will discuss the current mechanistic understanding of chronic diabetic complications and will explore the potential novel therapeutic interventions.
Export Options
About this article
Cite this article as:
Khan A. Zia, Farhangkhoee Hana and Chakrabarti Subrata, Towards Newer Molecular Targets for Chronic Diabetic Complications, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203081
DOI https://dx.doi.org/10.2174/157016106775203081 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research W-F Substitutions in Apomyoglobin Increase the Local Flexibility of the N-terminal Region Causing Amyloid Aggregation: A H/D Exchange Study
Protein & Peptide Letters An Overview on ATP Dependent and Independent Proteases Including an Anterograde to Retrograde Control on Mitochondrial Function; Focus on Diabetes and Diabetic Complications
Current Pharmaceutical Design Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Network Biology: Towards Systematic Understanding of Biological Systems)
Current Bioinformatics The Role of Probiotics and Prebiotics in Osteolastogenesis and Immune Relevance
Current Medicinal Chemistry Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Preface: Facing New Challenges in Cardiovascular Disease, When the Pressure Goes Up and the Pump Goes Astray
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection
Current Topics in Medicinal Chemistry Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients
Current Alzheimer Research Biomarkers of Diabetic Nephropathy, the Present and the Future
Current Diabetes Reviews Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
Drug Delivery Letters Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets